Nonapeptide-1
A melanocortin-1 receptor antagonist peptide that blocks alpha-MSH binding to inhibit melanin production - used in skin brightening, hyperpigmentation, and melanogenesis research.
Community Rating
No ratings yet
Compound Profile
Nonapeptide-1
Key Data
Research reference only
Research Focus
Preclinical data
⚠ Research & Educational Use Only. Nonapeptide-1 is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Selective melanocortin-1 receptor (MC1R) antagonist - blocks alpha-MSH binding to prevent melanin synthesis
- Inhibits tyrosinase activity - the rate-limiting enzyme in the melanin production pathway
- Reduces hyperpigmentation: age spots, post-inflammatory hyperpigmentation, melasma research
- Nonapeptide-1 is not FDA-approved for human use. Cosmetic ingredient. Approved for topical cosmetic use globally.
Research At a Glance
- Selective melanocortin-1 receptor (MC1R) antagonist - blocks alpha-MSH binding to prevent melanin synthesis
- Inhibits tyrosinase activity - the rate-limiting enzyme in the melanin production pathway
- Reduces hyperpigmentation: age spots, post-inflammatory hyperpigmentation, melasma research
- Identified from a library screen of 31,360 MC1R antagonist structures as a highly potent candidate
In Plain English
Simple summaryNonapeptide-1 (Mel-3, melanostat) is a 9-amino acid synthetic peptide designed to inhibit melanin production for skin brightening and hyperpigmentation reduction. It works by competitively binding to the melanocyte-stimulating hormone (alpha-MSH) receptor (MC1R), preventing alpha-MSH from activating melanin synthesis. Unlike hydroquinone (the traditional skin lightener that's toxic to melanocytes at higher concentrations), nonapeptide-1 is a reversible MC1R competitive antagonist -- it reduces melanin output without killing melanocytes. Brand-sponsored studies show it reduces UV-induced melanin production and may reduce existing hyperpigmentation with regular use, positioning it as a gentler alternative to conventional depigmenting agents.
- Selective melanocortin-1 receptor (MC1R) antagonist - blocks alpha-MSH binding to prevent melanin synthesis
- Inhibits tyrosinase activity - the rate-limiting enzyme in the melanin production pathway
- Reduces hyperpigmentation: age spots, post-inflammatory hyperpigmentation, melasma research
The full scientific detail, mechanisms, citations, and dosing data, follows below.
What is Nonapeptide-1?
Tap any underlined term for an instant definition.
Nonapeptide-1 is a synthetic nine-amino acid peptide designed and developed as a selective antagonist of the melanocortin-1 receptor (MC1R) - the primary switch controlling melanin production in skin. Unlike many skin-brightening ingredients that act downstream (inhibiting the tyrosinase enzyme that synthesises melanin), Nonapeptide-1 acts upstream by blocking the receptor that triggers the entire melanogenesis cascade.
The discovery of Nonapeptide-1 came from a systematic screen of over 31,360 structurally diverse peptides for MC1R antagonist activity. This massive combinatorial library approach identified Nonapeptide-1 as one of the most potent MC1R antagonists among the screened structures, with high binding affinity and selectivity for MC1R over related melanocortin receptors.
The melanogenesis pathway begins when UV radiation damages skin DNA, triggering keratinocytes to produce alpha-melanocyte-stimulating hormone (alpha-MSH). This hormone binds to MC1R on melanocytes, activating adenylyl cyclase and raising cAMP levels, which activates MITF (microphthalmia-associated transcription factor) - the master regulator of melanocyte gene expression. MITF then upregulates tyrosinase and other melanin synthesis enzymes, ultimately producing melanin pigment that is transferred to keratinocytes.
By blocking MC1R, Nonapeptide-1 interrupts this cascade at the receptor level - before cAMP elevation, MITF activation, and tyrosinase upregulation occur. This upstream intervention is more comprehensive than direct tyrosinase inhibition (as with kojic acid, arbutin, or vitamin C), because it prevents the entire downstream pigmentation programme from being initiated.
An important safety feature of Nonapeptide-1 is that it does not damage or destroy melanocytes - it simply reduces their melanin output by blocking their activation signal. This distinguishes it from hydroquinone (which is cytotoxic to melanocytes at therapeutic concentrations) and makes it suitable for long-term use without concern about permanent depigmentation or leucoderma.
By the Numbers
Key Research Benefits
Documented effects observed in preclinical and clinical studies on Nonapeptide-1. See all Skin & Anti-Aging peptides for comparison.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
Nonapeptide-1 is used topically at 5-10 ppm (parts per million) in formulations.
Topical concentration: 5-10 ppm Application: once to twice daily Often combined with: vitamin C (ascorbic acid), niacinamide, kojic acid for comprehensive brightening protocols Onset: visible brightness improvements typically after 4-8 weeks of consistent use
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
Apply topical serum or cream to cleansed skin. Focus on areas of hyperpigmentation or uneven skin tone. Always follow with SPF-containing sunscreen during daytime use (UV triggers melanin production, counteracting the peptide's effect). Consistent use over 8-12 weeks provides best results.
What the research doesn't show
Most nonapeptide-1 efficacy data is from supplier studies. The MC1R antagonism mechanism is well-supported pharmacologically, but the clinical magnitude of skin brightening in diverse skin types, the required concentration for visible results, and long-term safety have not been established in large independent trials. Hydroquinone, despite its toxicity concerns, has far more clinical evidence for hyperpigmentation than any cosmetic peptide alternative.
Medical Expert Videos
Physicians, researchers, and pharmacologists explain Nonapeptide-1, covering mechanisms of action, clinical context, and study findings.
Videos sourced from YouTube search. KnowYourPeptide does not endorse any individual creator. For research education only.
The Bottom Line
Nonapeptide-1 has a growing body of preclinical evidence and a well-characterised safety profile in research settings. The most-studied application is: selective melanocortin-1 receptor (mc1r) antagonist - blocks alpha-msh binding to prevent melanin synthesis.
The most commonly reported side effect in research subjects is generally very well tolerated. It is a research chemical, not approved for human use.
Frequently Asked Questions
Explore Further
Quick Reference
How It Compares
Tranexamic acid and kojic acid are tyrosinase inhibitors (blocking the enzyme that makes melanin) rather than MC1R antagonists (blocking the signal to make melanin) -- different points in the same pathway. Alpha-MSH itself and the melanotans are the agonists at the receptor nonapeptide-1 blocks. Among cosmetic depigmenting peptides, nonapeptide-1 has a clearer mechanistic rationale than most, though independent clinical evidence is limited.
Compare Nonapeptide-1 side-by-sideResearch Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.